Annals of Hematology

, Volume 89, Issue 5, pp 475–482 | Cite as

Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study

  • Yeo-Kyeoung Kim
  • Sang-Kyun Sohn
  • Jae-Hoon Lee
  • Deok-Hwan Yang
  • Joon-Ho Moon
  • Jae-Sook Ahn
  • Hyeoung-Joon Kim
  • Je-Jung LeeEmail author
  • The Korean Multiple Myeloma Working Party (KMMWP)
Original Article


The clinical efficacy and safety of a four-drug combination of bortezomib, cyclophosphamide, thalidomide, and dexamethasone was assessed for patients with relapsed or refractory multiple myeloma. Seventy patients received at least two cycles of treatment with bortezomib 1.3 mg/m2 intravenously on days 1, 4, 8, and 11; cyclophosphamide 150 mg/m2 orally on days 1–4; thalidomide 50 mg/day orally every day; and dexamethasone 20 mg/m2 intravenously on days 1, 4, 8, and 11. The overall best response rate was 88%, with 46% complete response, 9% very good partial response, and 33% partial response. After a median follow-up of 12.6 months, the median progression-free survival (PFS) was 14.6 months with a 3-year PFS of 14% and the median overall survival (OS) was 31.6 months with a 3-year OS of 47%. Grade 3 or 4 adverse events included thrombocytopenia (12%), neutropenia (4%), peripheral sensory neuropathy (3%), with thrombosis being very rare (<1%). Bortezomib combined with cyclophosphamide, thalidomide, and dexamethasone is a highly effective salvage therapy with manageable toxicity for patients with relapsed or refractory multiple myeloma.


Multiple myeloma Relapse Refractory Bortezomib Thalidomide 



The authors thank Dr. Paul Richardson, Dana-Faber Cancer Institute, for critically review the manuscript.


  1. 1.
    Kyle RA, Rajkumar SV (2004) Multiple myeloma. N Engl J Med 351:1860–1873CrossRefPubMedGoogle Scholar
  2. 2.
    Galton DA, Peto R (1968) A progress report on the Medical Research Council's therapeutic trial in myelomatosis. Br J Haematol 15:319–320CrossRefPubMedGoogle Scholar
  3. 3.
    Sirohi B, Powles R (2004) Multiple myeloma. Lancet 363:875–887CrossRefPubMedGoogle Scholar
  4. 4.
    Alexanian R, Barlogie B, Tucker S (1990) VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol 33:86–89CrossRefPubMedGoogle Scholar
  5. 5.
    Barlogie B, Jagannath S, Desikan KR et al (1999) Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 93:55–65PubMedGoogle Scholar
  6. 6.
    Samson D, Gaminara E, Newland A et al (1989) Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma. Lancet 2:882–885CrossRefPubMedGoogle Scholar
  7. 7.
    Sirohi B, Powles R, Mehta J et al (1999) Complete remission rate and outcome after intensive treatment of 177 patients under 75 years of age with IgG myeloma defining a circumscribed disease entity with a new staging system. Br J Haematol 107:656–666CrossRefPubMedGoogle Scholar
  8. 8.
    Goldschmidt H, Hegenbart U, Wallmeier M et al (1997) Factors influencing collection of peripheral blood progenitor cells following high-dose cyclophosphamide and granulocyte colony stimulating factor in patients with multiple myeloma. Br J Haematol 98:736–744CrossRefPubMedGoogle Scholar
  9. 9.
    Richardson PG, Hideshima T, Mitsiades C et al (2007) The emerging role of novel therapies for the treatment of relapsed myeloma. J Natl Compr Canc Netw 5:149–162PubMedGoogle Scholar
  10. 10.
    San Miguel JF, Schlag R, Khuageva NK et al (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359:906–917CrossRefPubMedGoogle Scholar
  11. 11.
    Dimopoulos M, Spencer A, Attal M et al (2007) Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357:2123–2132CrossRefPubMedGoogle Scholar
  12. 12.
    Weber DM, Chen C, Niesvizky R et al (2007) Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 357:2133–2142CrossRefPubMedGoogle Scholar
  13. 13.
    Richardson PG, Barlogie B, Berenson J et al (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609–2617CrossRefPubMedGoogle Scholar
  14. 14.
    Jagannath S, Barlogie B, Berenson J (2004) A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 127:165–172CrossRefPubMedGoogle Scholar
  15. 15.
    Richardson PG, Sonneveld P, Schuster M et al (2007) Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 110:3557–3560CrossRefPubMedGoogle Scholar
  16. 16.
    Wang LM, Weber DM, Delasalle KB et al (2004) VTD (Velcade, thalidomide, dexamethasone) as primary therapy for newly diagnosed multiple myeloma. Blood 104:210aGoogle Scholar
  17. 17.
    Oakervee HE, Popat R, Curry N et al (2005) PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol 129:755–762CrossRefPubMedGoogle Scholar
  18. 18.
    Dimopoulos MA, Zervas K, Kouvatseas G et al (2001) Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol 12:991–995CrossRefPubMedGoogle Scholar
  19. 19.
    Weber DM, Rankin K, Gavino M et al (2000) Thalidomide with dexamethasone for resistant multiple myeloma. Blood 96:167aGoogle Scholar
  20. 20.
    Palumbo A, Giaccone L, Bertola A et al (2001) Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica 86:399–403PubMedGoogle Scholar
  21. 21.
    Garcia-Sanz R, Gonzalez-Fraile MI, Sierra M, Lopez C et al (2003) The combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is feasible and can be an option for relapsed/refractory multiple myeloma. Hematol J 3:43–48CrossRefGoogle Scholar
  22. 22.
    Srkalovic G, Elson P, Trebisky B et al (2002) Use of melphalan, thalidomide, and dexamethasone in treatment of refractory and relapsed multiple myeloma. Med Oncol 19:219–226CrossRefPubMedGoogle Scholar
  23. 23.
    Richardson PG, Briemberg H, Jagannath S et al (2006) Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 24:3113–3120CrossRefPubMedGoogle Scholar
  24. 24.
    Durie BG, Harousseau JL, Miguel JS et al (2006) International uniform response criteria for multiple myeloma. Leukemia 20:1467–1473CrossRefPubMedGoogle Scholar
  25. 25.
    Chanan-Khan A, Sonneveld P, Schuster MW et al (2008) Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol 26:4784–4790CrossRefPubMedGoogle Scholar
  26. 26.
    Terpos E, Kastritis E, Roussou M et al (2008) The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis. Leukemia 22:2247–2256CrossRefPubMedGoogle Scholar
  27. 27.
    Palumbo A, Ambrosini MT, Benevolo G et al (2007) Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood 109:2767–2772PubMedGoogle Scholar
  28. 28.
    Musto P, Falcone A, Sanpaolo G et al (2006) Bortezomib (Velcade) for progressive myeloma after autologous stem cell transplantation and thalidomide. Leuk Res 30:283–285CrossRefPubMedGoogle Scholar
  29. 29.
    Popat R, Oakervee H, Williams C et al (2009) Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma. Br J Haematol 144:887–894CrossRefPubMedGoogle Scholar
  30. 30.
    Reece DE, Rodriguez GP, Chen C et al (2008) Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma. J Clin Oncol 26:4777–4783CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Yeo-Kyeoung Kim
    • 1
  • Sang-Kyun Sohn
    • 2
  • Jae-Hoon Lee
    • 3
  • Deok-Hwan Yang
    • 1
  • Joon-Ho Moon
    • 2
  • Jae-Sook Ahn
    • 1
  • Hyeoung-Joon Kim
    • 1
  • Je-Jung Lee
    • 1
    • 4
    • 5
    Email author
  • The Korean Multiple Myeloma Working Party (KMMWP)
    • 4
  1. 1.Chonnam National University Medical SchoolGwangjuRepublic of Korea
  2. 2.Kyungpook National University Medical SchoolDaeguRepublic of Korea
  3. 3.Gachon UniversityIncheonRepublic of Korea
  4. 4.The Brain Korea 21 ProjectCenter for Biomedical Human Resources at Chonnam National UniversityGwangjuRepublic of Korea
  5. 5.Department of Hematology–OncologyChonnam National University Hwasun HospitalHwasun-gunRepublic of Korea

Personalised recommendations